Abstract
Gut microbes have ascended to prominence as key modulators of host immunity, raising the possibility that they could influence the outcome of cancer immunotherapy. Two recent studies address this question by identifying specific gut-resident bacteria as drivers of checkpoint blockade immunotherapy in pre-clinical tumor models.
Copyright © 2015 Elsevier Inc. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
-
Comment
MeSH terms
-
Animals
-
Anthracyclines / adverse effects*
-
Antibiotics, Antineoplastic / adverse effects*
-
Antibodies, Monoclonal / therapeutic use*
-
B7-H1 Antigen / immunology*
-
Bifidobacterium / immunology*
-
Gastrointestinal Microbiome / immunology*
-
Humans
-
Melanoma / immunology*
-
Melanoma / therapy*
-
Receptors, Retinoic Acid / genetics*
-
Skin Neoplasms / immunology*
-
Skin Neoplasms / therapy*
-
Ventricular Dysfunction, Left / genetics*
Substances
-
Anthracyclines
-
Antibiotics, Antineoplastic
-
Antibodies, Monoclonal
-
B7-H1 Antigen
-
Receptors, Retinoic Acid